Managing the front‐line treatment for diffuse large B cell lymphoma and high‐grade B cell lymphoma during the COVID‐19 outbreak
B. de la Cruz Benito, Paula Lázaro del Campo, Andrés Ramírez López, Teresa de Soto‐Álvarez, Irene Sánchez‐Vadillo, Eduardo García‐Pérez, Abel Dos Santos‐Ortas, Karem Humala‐Barbier, Ana López‐de la Guía, Gema Casado‐Abad, Víctor Jiménez‐Yuste, Miguel Canales
Abstract
The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.